Application of serum natalizumab levels during plasma exchange in MS patients with progressive multifocal leukoencephalopathy

Abstract

Progressive multifocal leukoencephalopathy (PML) is a severe complication of natalizumab treatment. Restoring immune function by plasmapheresis/immunoadsorption (PLEX/IA) is important for the outcome of PML. We report on four multiple sclerosis (MS) patients whom developed PML during natalizumab treatment, in whom we measured serum natalizumab concentrations before and during PLEX. Depending on the serum natalizumab concentration at the time of PML diagnosis, the number of PLEX treatments necessary to reach subtherapeutic serum natalizumab concentrations is variable. Measuring serum natalizumab concentrations before and during PLEX is helpful to determine the optimum number of PLEX treatments in individual MS patients with PML.

Keywords

Adverse effects case studies immunoadsorption multiple sclerosis natalizumab plasmapheresis progressive multifocal leukoencephalopathy

Get full access to this article

View all access options for this article.

References

Stüve

Marra

Cravens

. Potential risk of progressive multifocal leukoencephalopathy with natalizumab therapy: Possible interventions. Arch Neurol 2007; 64: 169–176.

Clifford

DeLuca

Simpson

. Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: Lessons from 28 cases. Lancet Neurol 2010; 9: 438–446.

Rispens

Vennegoor

Wolbink

. Natalizumab remains detectable in patients with multiple sclerosis long after treatment is stopped. Mult Scler 2012; 18: 899–901.

Khatri

Man

Giovannoni

. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology 2009; 72: 402–409.

Rispens

Leeuwen

Vennegoor

. Measurement of serum levels of natalizumab, an immunoglobulin G4 therapeutic monoclonal antibody. Anal Biochem 2011; 411: 271–276.

Berger

Aksamit

Clifford

. PML diagnostic criteria: Consensus statement from the AAN Neuroinfectious Disease Section. Neurology 2013; 80: 1430–1438.

Calabresi

Giovannoni

Confavreux

. The incidence and significance of anti-natalizumab antibodies: Results from AFFIRM and SENTINEL. Neurology 2012; 79: 1391–1403.

Vennegoor

Rispens

Strijbis

EMM

.Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis. Mult Scler 2013; 19: 593–600.

Shapiro

Plavina

Schlain

. Development and validation of immunoassays to quantify the half-antibody exchange of an IgG4 antibody, natalizumab (Tysabri®) with endogenous IgG4. J Pharm Biomed Anal 2011; 55: 168–175.